Merit Medical Systems, Inc.  

(Public, NASDAQ:MMSI)   Watch this stock  
Find more results for Nolan E. Karras
14.72
-0.09 (-0.61%)
Nov 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.67 - 14.99
52 week 11.41 - 16.76
Open 14.99
Vol / Avg. 116,414.00/235,270.00
Mkt cap 638.89M
P/E 30.57
Div/yield     -
EPS 0.48
Shares 43.40M
Beta 0.81
Inst. own 84%
Nov 20, 2014
Merit Medical Systems Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 12, 2014
Merit Medical Systems Inc at Stephens Fall Investment Conference
Oct 23, 2014
Q3 2014 Merit Medical Systems Inc Earnings Call - Webcast
Oct 23, 2014
Q3 2014 Merit Medical Systems Inc Earnings Release
Sep 9, 2014
Merit Medical Systems Inc at CL King & Associates Inc Best Ideas Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 6.03% 3.69%
Operating margin 9.38% 6.20%
EBITD margin - 15.26%
Return on average assets 4.18% 2.31%
Return on average equity 7.41% 4.21%
Employees 2,888 -
CDP Score - -

Address

1600 WEST MERIT PARK WAY
SOUTH JORDAN, UT 84095
United States - Map
+1-801-2531600 (Phone)
+1-801-2531652 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Merit Medical Systems, Inc. (Merit) designs, develops, manufactures and markets medical devices used in interventional and diagnostic procedures. The Company operates in the cardiology, radiology, pulmonology, thoracic surgery, nephrology, vascular surgery and gastroenterology markets. It operates in two segments: cardiovascular segment, which consists of cardiology and radiology devices that assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases, and includes the embolotherapeutic products, and endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. In February 2012, the Company acquired the assets of Ostial Solutions, LLC. In December 2012, the Company acquired Thomas Medical Products, Inc.

Officers and directors

Fred P. Lampropoulos Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kent W. Stanger Chief Financial Officer, Secretary, Treasurer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ronald A. Frost Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Martin R. Stephens Executive Vice President - Marketing and Sales
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rashelle Perry Chief Legal Officer
Age: 48
Bio & Compensation  - Reuters
A. Scott Anderson Independent Director
Age: 67
Bio & Compensation  - Reuters
Richard W Edelman Independent Director
Age: 73
Bio & Compensation  - Reuters
Nolan E. Karras Independent Director
Age: 69
Bio & Compensation  - Reuters
Franklin J. Miller Independent Director
Age: 73
Bio & Compensation  - Reuters
Michael E. Stillabower M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters